---
layout: default
title: Palivizumab
parent: 僅模型預測 (L5)
nav_order: 290
evidence_level: L5
indication_count: 10
---

# Palivizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Palivizumab: From RSV Prophylaxis to Benign Neoplasm of Tongue

## One-Sentence Summary

> Palivizumab is a humanized monoclonal antibody against the RSV F glycoprotein, used to prevent respiratory syncytial virus (RSV) infection in high-risk infants.
> The TxGNN model predicts it may be effective for **Benign Neoplasm of Tongue**,
> but **no clinical trials** and **no literature** currently support this direction — the model's own mechanistic rationale explicitly states there is no known biological link.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in the evidence pack (data gap — DG001/DG002). Based on internal rationale text, palivizumab is a humanized anti-RSV F-glycoprotein monoclonal antibody used for RSV prophylaxis. |
| Predicted New Indication | Benign Neoplasm of Tongue |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 (model prediction only, no clinical or literature evidence) |
| Germany Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack (original_moa = Data Gap; DG002). Based on the mechanistic notes attached to each predicted indication, palivizumab is consistently described as a humanized monoclonal antibody that neutralizes the RSV F (fusion) glycoprotein, blocking viral entry into respiratory epithelial cells. This is a highly specific antiviral mechanism with no known role in cell proliferation, oncogenesis, or tumor biology.

Critically, the repurposing rationale supplied for this candidate does **not** support the prediction — it explicitly states: *"Palivizumab為抗RSV F醣蛋白之人源化單株抗體，僅作用於RSV感染細胞表面抗原，與舌部良性腫瘤之增生／腫瘤生物學機轉無已知關聯。無腫瘤免疫或抗病毒交叉機轉支持此連結。"* (i.e., no known immune-oncology or antiviral cross-mechanism links palivizumab to tongue neoplasm biology.) The same pattern holds across all 10 ranked predictions for this drug — each rationale independently disclaims any plausible mechanistic connection to the paired disease (epiglottis neoplasm, cervical neuroblastoma, testicular tumor, schwannoma, etc.).

This is therefore a case where a high TxGNN embedding-similarity score is **not corroborated** by mechanistic, clinical, or literature evidence. The prediction should be treated as a graph-similarity artifact rather than a biologically grounded repurposing hypothesis.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Germany Market Information

Palivizumab currently holds no market authorizations in the reviewed dataset (total_licenses = 0; market_status = Not Marketed). No license records are available to summarize.

---

## Safety Considerations

Please refer to the package insert for safety information. (Note: TFDA/BfArM label warnings and contraindications for palivizumab are a **Blocking** data gap — DG001 — and safety review cannot proceed to Stage 1 evaluation until this is resolved.)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests solely on a TxGNN similarity score (L5, no clinical trials, no literature), and the accompanying mechanistic rationale explicitly rejects any biological plausibility between palivizumab's RSV-neutralizing mechanism and tongue neoplasm pathophysiology. There is no evidentiary basis to advance this candidate.

**To proceed, the following is needed:**
- Resolve DG001 (TFDA/BfArM label warnings and contraindications) before any safety-stage review
- Resolve DG002 (confirmed mechanism of action from DrugBank) to formally support or rule out mechanistic linkage
- Independent confirmation of original indication and approval history (original_indications is currently empty)
- If this candidate is to be pursued further, a fresh mechanistic hypothesis independent of the current TxGNN rationale would be required, since the existing rationale argues against repurposing
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

